Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | LTK | P29376 | 1/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30340726 | 1.00 | CA12 (0.40) | CA12CA9ALOX15HSD17B10JAK2 | |
| SCHEMBL20503690 | 0.94 | CA12 (0.40) | CA12CA9ALOX15HSD17B10JAK2 | |
| SCHEMBL30096606 | 0.94 | CA12 (0.40) | CA12CA9ALOX15HSD17B10JAK2 | |
| SCHEMBL23044043 | 0.78 | KDM4E (0.41) | PLK4DAPK3PIM1PDGFRALTK | |
| SCHEMBL21340386 | 0.76 | ACVR1 (0.39) | GAAPDGFRALTKCDK8CDK5 | |
| SCHEMBL20854469 | 0.75 | METAP2 (0.53) | CA12CA9ALOX15HSD17B10JAK2 | |
| Dihydrophenanthridine SCHEMBL29791568 | 0.73 | CA12 (0.56) | CA12CA9ALOX15HSD17B10JAK2 | |
| Dihydrophenanthridine SCHEMBL2087461 | 0.73 | CA12 (0.56) | CA12CA9ALOX15HSD17B10JAK2 | |
| SCHEMBL24976109 | 0.73 | ALDH1A1 (0.37) | HSD17B10GAAPLK4DAPK3PIM1 | |
| SCHEMBL727511 | 0.73 | ALDH1A1 (0.37) | HSD17B10GAAPLK4DAPK3PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096366-A1 | CONJUGATES FOR DELIVERY ACROSS THE BLOOD BRAIN BARRIER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-05-08 | — | — | WO | claimed |
| US-20260144856-A1 | VACCINE AGAINST KLEBSIELLA PNEUMONIAE | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-05-28 | — | — | US | disclosed |
| US-20250228954-A1 | Designing Antisense Oligonucleotide Delivery Peptides by Interpretable Machine Learning | SAREPTA THERAPEUTICS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250224411-A1 | MOLECULAR HOPPER | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-07-10 | — | — | US | disclosed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250161469-A1 | TRIMERIC PEPTIDES FOR ANTISENSE DELIVERY | SAREPTA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2025096366-A1 | CONJUGATES FOR DELIVERY ACROSS THE BLOOD BRAIN BARRIER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12247990-B2 | Molecular hopper | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-03-11 | — | — | US | disclosed |
| WO-2025030099-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-20250011777-A1 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2025-01-09 | — | — | US | disclosed |
| EP-3829597-A1 | TRIMERIC PEPTIDES FOR ANTISENSE DELIVERY | Sarepta Therapeutics, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020252015-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | SUTRO BIOPHARMA, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200353076-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES | SUTRO BIOPHARMA, INC. | 2020-11-12 | — | — | US | disclosed |
| WO-2020028254-A1 | TRIMERIC PEPTIDES FOR ANTISENSE DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2020-02-06 | — | — | WO | disclosed |
| US-10435479-B2 | Chemically-locked bispecific antibodies | SORRENTO THERAPEUTICS, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190248923-A1 | CHEMICALLY-LOCKED BISPECIFIC ANTIBODIES | SORRENTO THERAPEUTICS, INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-10301395-B2 | Chemically-locked bispecific antibodies | SORRENTO THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| EP-3377112-A1 | CHEMICALLY-LOCKED BISPECIFIC ANTIBODIES | Sorrento Therapeutics, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20170137539-A1 | CHEMICALLY-LOCKED BISPECIFIC ANTIBODIES | SORRENTO THERAPEUTICS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20160215020-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011777-A1 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | MYOF, IAPP, MTPN | CA12 2588/4885CA9 4084/4885ALOX15 3698/4885 |
| US-20200353076-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES | FOLR2, FOLR1, FCGRT | CA12 512/4885CA9 3822/4885ALOX15 2600/4885 |
| US-20190248923-A1 | CHEMICALLY-LOCKED BISPECIFIC ANTIBODIES | CD274, CD22, CXCR3 | CA12 763/4885CA9 1380/4885ALOX15 3371/4885 |
| US-20160215020-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | CA12 2632/4885CA9 3161/4885ALOX15 1784/4885 |
| US-10301395-B2 | Chemically-locked bispecific antibodies | CD274, CD47, CD22 | CA12 922/4885CA9 1439/4885ALOX15 3475/4885 |
| US-20260144856-A1 | VACCINE AGAINST KLEBSIELLA PNEUMONIAE | PKLR, RPS17, OSTC | CA12 398/4885CA9 1475/4885ALOX15 3776/4885 |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | CA12 3111/4885CA9 3474/4885ALOX15 2687/4885 |
| US-20170137539-A1 | CHEMICALLY-LOCKED BISPECIFIC ANTIBODIES | CD274, CD47, CD22 | CA12 922/4885CA9 1439/4885ALOX15 3475/4885 |
| US-20250161469-A1 | TRIMERIC PEPTIDES FOR ANTISENSE DELIVERY | MTPN, MYOF, IAPP | CA12 2137/4885CA9 3240/4885ALOX15 4120/4885 |
| US-10435479-B2 | Chemically-locked bispecific antibodies | FCGR3B, FCGR2A, FCGR1A | CA12 1200/4885CA9 2730/4885ALOX15 3039/4885 |
| US-20250228954-A1 | Designing Antisense Oligonucleotide Delivery Peptides by Interpretable Machine Learning | MTPN, TNNC1, MYOF | CA12 2624/4885CA9 3486/4885ALOX15 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.